|
Day one plenary morning - Monday 16th April 2007
|
| 08.00 | Registration and coffee
|
| |
|
| 08.50 | Chairman’s opening remarks
|
| | Lallan Giri, Vice President, Scientific Affairs, Emergent BioSolutions Inc.
|
| 09.00 | Keynote address: building the future of the pharmaceutical industry via partnering
-
M&A activity as part of an overall growth strategy
-
Different types of partners and their opportunities and risks
-
Benefits of partnering in emerging markets |
| | Fuad El-Hibri, Chief Executive Officer and Chairman, Emergent BioSolutions Inc.
|
| LICENSING VS. ACQUISITION DEBATE |
|
| 09.25 | Acquisition from the perspective of a biotechnology company
- Building the company through corporate relationships
- Relationship life-cycles
- Why companies get acquired
- What happens next and why?
|
| |
|
| 09.50 | Licensing vs. mergers and acquisitions
- The pharmaceutical company perspective on licensing vs. M&A
- The strategies and considerations behind the decision to license or acquire
- Key strengths on offer in the biotech sector
- Is the current trend in licensing and M&A activity likely to continue throughout 2007 and beyond?
|
| | Hans Bostrom, Director, Scientific Liaison, Merck, Sharp and Dohme
|
| 10.15 | Morning coffee
|
| |
|
| 11.00 | Panel session: the different perspectives on acquisition
- What are the key factors driving the popularity of acquisitions?
- How do the acquisition models of different pharmaceutical companies vary?
- The varying challenges of licensing vs. acquisition
|
| | Moderator: Lallan Giri, Vice President, Scientific Affairs, Emergent BioSolutions Inc. Confirmed: Nigel Burns, Independent Advisor, Independent Advisor Confirmed: David Colpman, Senior Vice President of Business Development, Shire Pharmaceuticals Confirmed: Avinoam Kadouri, Chief Executive Officer, Rainbow Biotechnologies
|
| THE DECISION MAKING PROCESS |
|
| 11.45 | What qualities do pharmaceutical companies look for in a potential partner
- The importance of partnering with biotechs, spin-out companies and academics
- What opportunities are available in these organisations
- How do pharmaceutical companies evaluate biotechs and academics?
- What is the best way to stand out and be noticed by a pharmaceutical company?
|
| | Karen Huebscher, Global Head of Business Development and Licensing, Novartis Vaccines and Diagnostics
|
| 12.10 | Industry trends and their effect on license and collaboration agreement terms
- Balancing of deal terms between pharma and biotech
- Obligations to develop, exploit and promote
- Long-term alliance management
|
| |
|
| 12.35 | Speed Networking
These brief meetings are the starting point for conversation and networking throughout the conference. This is where long lasting and fruitful relationships begin. Please make sure you bring lots of business cards!
Meet….move on…meet…move on…meet! |
| |
|
| 13.30 | Lunch
|
| |
|
|
Day one stream one - where does the smart money invest?
|
| 14.35 | Chairman’s opening remarks
|
| | Lallan Giri, Vice President, Scientific Affairs, Emergent BioSolutions Inc.
|
| 14.45 | Do opportunities in oncology still exist and how can you capitalise?
- Are there still enough opportunities in oncology to make it a worthwhile investment?
- What areas are still worth investing in?
- What new technologies are there?
- What are the key new investment areas?
|
| |
|
| 15.15 | Case study: the importance of biomarker data when forging alliances
- How does biotech perceive pharma's needs for biomarkers?
- How can biotech address pharma's real needs?
- Where have biomarker data enabled a successful partnership?
|
| |
|
| 15.45 | Afternoon tea
|
| |
|
| 16.30 | Case study: partnering opportunities and vaccines
- What current alliance opportunities exist for vaccines?
- Who are the key players in vaccine development?
- What is the future of vaccines in relation to licensing and acquisitions?
- Review of vaccines for infectious disease
|
| |
|
| 17.00 | Case study: partnering opportunities and gene therapy
- What current alliance opportunities exist for gene therapy?
- What is the future of gene therapy in relation to licensing and acquisitions?
- Has the success of gene therapy trials improved recently and what does this mean for partnering?
|
| | Stephen Hart, Chief Scientific Officer, Genex Biosystems Ltd
|
| 17.30 | Q&A panel session: key focus areas for partnering
- What are the other key areas for partnering?
|
| | Confirmed: Piers Whitehead, VP Corporate and Business Development, Business Development, VaxGen, Inc. Confirmed: Stephen Hart, Chief Scientific Officer, Genex Biosystems Ltd
|
| 18.00 | Chairman’s closing remarks and close of day one
|
| |
|
| 18.10 | Welcome drinks reception
|
| |
|
|
Day one stream two - sourcing partners through drug delivery
|
| 14.35 | Chairman’s opening remarks
|
| |
|
| 14.45 | Case study: development of new inhaler technologies through collaborations
- Key technologies, developments and key players in the inhaler devices market
- Recent deal making trends in inhaler and device technologies
- Boehringer Ingelheim’s inhaler development through acquisition and cooperation
|
| | Frank Kalkbrenner, Vice President, Research and Development Licensing and Information Management, Boehringer Ingelheim
|
| 15.15 | The inhalation drug delivery market and investment areas
- What does the inhalation market currently look like?
- What therapies are successfully using this method of delivery?
- What market benefits does delivery via inhalation provide and who is partnering where?
|
| |
|
| 15.45 | Afternoon tea
|
| |
|
| 16.30 | Case study - recent developments in needle free Injection
-
Current status of the NFI market
-
Key drivers of market growth
-
Opportunities for combination products
-
Selecting the right partners and deal structures
-
Ensuring successful integrated product co-development |
| |
|
| 17.00 | Going it alone: developing a drug delivery system without partnering
- What are the obstacles faced when developing a drug delivery system alone?
- The role of venture capitals and financial institutions
- Strategic and geographical marketing to avoid licensing
- At what point should licensing be considered?
- Working with drug delivery manufacturers
|
| |
|
| 17.30 | Q&A panel session: drug delivery pipeline opportunities and where to invest
- Your opportunity to ask the speakers the questions you want answered
|
| | Moderator: Frank Kalkbrenner, Vice President, Research and Development Licensing and Information Management, Boehringer Ingelheim Confirmed: Simon Bennett, Business Development Director, Glide Pharma
|
| 18.00 | Chairman’s closing remarks and close of day one
|
| |
|
| 18.10 | Welcome drinks reception
|
| |
|
|
Day two plenary morning - Tuesday 17th April 2007
|
| 08.00 | Registration and coffee
|
| |
|
| 08.50 | Chairman’s opening remarks
|
| |
|
| EVALUATING EARLY STAGE OPPORTUNITIES TO BOOST PIPELINES |
|
| 09.00 | Partnering at different development stages
- Why do pharmaceutical companies favour late stage investments?
- How can early stage deals be made more favourable?
- How early stage investments can be used to expand pharma pipelines
- Early stage opportunities available in Europe vs. America
|
| | Malcolm Skingle, Director, Academic Liaison, Worldwide Business Development, Glaxosmithkline
|
| 09.30 | Panel session: the benefits of partnering with university technology transfer offices
- The opportunities arising from university technology transfer offices
- What are the best ways for a technology transfer office to promote their opportunities?
- An overview of success stories
|
| | Confirmed: Tony Hickson, Head of Bioscience, Imperial Innovations Confirmed: Iain Thomas, Head of Life Sciences, Cambridge Enterprise Confirmed: Tim Hammond, Technology Transfer Manager, Durham University
|
| 10.15 | Morning coffee
|
| |
|
| 11.15 | Case study: alternative sources of funding for technology transfer
- Gap funding; how it can lead to better partnerships
- Lost in translation - the innovation gap
- Developing better partnerships
|
| | Richard Seabrook, Head of Business Development, Technology Transfer Division, The Wellcome Trust
|
| 11.45 | Case study: key successes of a technology transfer partnership
- What does success look like after the deal making process?
- A detailed look at a successful partnerships between academia and biotechnology / pharmaceutical companies
- What were the issues encountered? What were the timelines involved?
|
| |
|
| THE SHIFT TOWARDS PERSONALISED HEALTHCARE |
|
| 12.15 | How personalised healthcare will reduce pharmaceutical pipelines
- How will the shift from blockbuster drugs to personalised medicine affect pipelines?
- How will this affect partnering and acquisition activity?
- Will this mean more early stage deals?
|
| |
|
| 12.45 | Lunch sponsored by PWC
 |
| |
|
|
Day two stream one - becoming acquisition ready
|
| 14.00 | Chairman’s opening remarks
|
| |
|
| BECOMING ACQUISITION READY |
|
| 14.15 | Getting your biopharmaceutical product from discovery to market: becoming acquisition-ready
Four 15-minute presentations on ensuring your company is ready for acquisition or licensing. These will cover both technical and commercial considerations and will be followed by a panel Q&A session.
- Filling pharma’s pipeline - the role for biotechs and capturing value
Duncan Casson, Chief Operating Officer, Pangenetics
- Making the move from academia to industry
Keith Powell, Chief Executive Officer, Domainex and Polytherics
- Paying attention to the regulatory process
Crawford Brown, Chief Executive Officer, Eden BioDesign
- The process is the product - leveraging bioprocessing to get your biopharmaceuticals into the clinic
Brendan Fish, Director, Bioprocess Sciences, Cambridge Antibody Technology |
| |
|
| 15.15 | Q&A Panel session: Developing an environment where small biotechs can thrive
|
| | Moderator: Tony Bradshaw, Director bioProcessUK, BioIndustry Association Confirmed: Brendan Fish, Director, Bioprocess Sciences, Cambridge Antibody Technology
|
| 15.45 | Afternoon tea
|
| |
|
| 16.45 | Case study: how pharmaceutical companies evaluate biotechs and technology transfers
- What key strategies do pharmaceutical companies use to assess opportunities arising from biotechs?
- How do pharmaceutical companies find the right collaborators and what does the decision making process look like?
- How can biotechs make their proposition appealing?
- Review of successful partnerships and alliances
|
| | Andrew Wood, Executive Director, Global External Research and Development, Eli Lilly
|
| 17.15 | How to maximise your clinical trials to guarantee partnership success
- How to maximise trial design and operation
- What is big pharma looking for?
- Trial design site selection
|
| |
|
| 17.45 | Chairman’s closing remarks and close of day two
|
| |
|
|
Day two stream two - partnering and investing in emerging markets
|
| 14.00 | Chairman’s opening remarks
|
| |
|
| PARTNERING AND INVESTING IN EMERGING MARKETS |
|
| 14.15 | Partnering opportunities in India
- What are the key advantages of doing business with India?
- What is available through suppliers in India?
- What are the future Indian business models?
- What are the key challenges?
|
| |
|
| 14.45 | Case study: Indian partnerships in EMEA and North America
- What made these strategic partnerships so successful?
- The benefits of partnering with an Indian pharmaceutical company
- What key opportunities are available in India?
|
| | Dinesh Dua, President, International and Biotechnology Strategic Un, Wockhardt
|
| 15.15 | Case study: outsourcing your clinical trials to India
- What is the Indian government doing to facilitate this?
- The clinical trails expertise available in India
- Clinical trails centres of excellence
|
| |
|
| 15.45 | Afternoon Tea
|
| |
|
| 16.45 | Partnering with Chinese manufacturers
- An overview of the Chinese vaccine market
- Partnering with Chinese manufacturers: a business model
- Looking for international alliances
|
| | Jean-Denis Shu, Chairman and Chief Executive Officer, Bio-Crown Technology Ltd
|
| GENERICS AND PARTNERING: KEY CONSIDERATIONS |
|
| 17.15 | Generics partnering opportunities
- What are the key opportunities in the generics industry?
- Why are generics such a hot area for partnering?
- Supply and value chain in the generics industry
- Investing in generics companies in emerging markets
|
| |
|
| 17.45 | Chairman’s closing remarks and close of day two
|
| |
|
|
Day three steam one - the practicalities of partnering
|
| 08.00 | Registration and coffee
|
| |
|
| 08.50 | Chairman’s opening remarks
|
| | Chris Holloway, Group Director of Regulatory Affairs, ERA Consulting und Pharmaberatungs GmbH
|
| PRACTICALITIES OF PARTNERING |
|
| 09.00 | Expanding through partnering
- Challenges faced when starting up and how to overcome these
- How to avoid the debt trap
- Using strategic partnering to expand
|
| | Lallan Giri, Vice President, Scientific Affairs, Emergent BioSolutions Inc.
|
| 09.30 | Case study: adding value to biotech product development from the European regulatory perspective
- What is a regulatory strategy and why is it important?
- How can regulatory intelligence maximise the efficiency of product development?
- Fundamental regulatory issues: non-clinical, clinical and quality
|
| | Chris Holloway, Group Director of Regulatory Affairs, ERA Consulting und Pharmaberatungs GmbH
|
| 10.00 | Partnerships for developing enteric disease vaccines
- Finding your way through the multiple ways to partner
- Making partnering choices in funding, clinical resources, manufacturing and distribution
- Key considerations specific to vaccine development
|
| | Ronald Ellis, Senior Vice President, Research and Development, Avant Immunotherapeutics
|
| 10.30 | Morning coffee
|
| |
|
| 11.30 | key biotech strengths which led to a successful vaccines partnership
- What important strengths should a biotech demonstrate?
- What qualities are particularly important to the vaccines industry?
- Examples of successful vaccines partnerships
|
| |
|
| 12.00 | Good deal making and due diligence
- Current trends in deal making, M&A, licensing, the increasing costs of deal making, who are the partner's of choice?
- What do these trends mean to earlier stage companies, spin outs and academics?
- What is due diligence and why do we need it?
|
| |
|
| 12.30 | Speed networking
These brief meetings are the starting point for conversation and networking throughout the conference. This is where long lasting and fruitful relationships begin. Please make sure you bring lots of business cards!
Meet….move on…meet…move on…meet! |
| |
|
| 13.30 | Lunch
|
| |
|
|
Day three stream two - overcoming the challenges of effective partnering
|
| 08.00 | Registration and coffee
|
| |
|
| 08.50 | Chairman’s opening remarks
|
| |
|
| OVERCOMING THE CHALLENGES OF EFFECTIVE PARTERING |
|
| 09.00 | Case study: due diligence in deal making for pharmaceutical companies
- What are the due diligence considerations for licensing and acquisitions?
- What is the best way to manage due diligence?
- How can you best protect yourself and reduce the risk of a failed partnership?
|
| |
|
| 09.30 | Biopharmaceutical contract manufacturing
- Capacity and outsourcing needs
- User outsourcing strategies
- Services outsourced
- Contractor selection
|
| |
|
| STRATEGICALLY FILLING YOUR PIPELINE |
|
| 10.00 | Opportunities created by pharmaceutical spin-out (or walk-out) companies
- What opportunities do spin-out companies represent?
- Review of key success stories
- What are the legal implications of creating a spin-out company from on the shelf drugs?
- What are the legal implications of in-licensing from a spin-out company?
|
| | Ben Tan, Head of Business Development and Licensing, Speedel
|
| 10.30 | Morning coffee
|
| |
|
| 11.30 | International portfolio development and alliances between academia and industry
- Redesigning international management approaches
- Focusing academia on the value chain
- Portfolio development and market dynamic
|
| |
|
| 12.00 | Case study: addressing pharmaceutical in-licensing demands
- Examples of successful oncology focused co-development programmes eg. Vernalis / Novartis Hsp90 programme arising from a collaboration between Vernalis, the Institute of Cancer Research and CRT
- Clinical development partnerships
- How is academia addressing biopharmaceutical in-licensing demands?
- Review of oncology focused drug discovery in academia
|
| | Confirmed: Phil L'Huillier, Director, Business Management, Cancer Research Technology Limited
|
| 12.30 | Speed networking
These brief meetings are the starting point for conversation and networking throughout the conference. This is where long lasting and fruitful relationships begin. Please make sure you bring lots of business cards!
Meet….move on…meet…move on…meet! |
| |
|
| 13.30 | Lunch
|
| |
|
|
Day three plenary afternoon - future outlook for partnering
|
| 14.25 | Chairman’s opening remarks
|
| | Chris Holloway, Group Director of Regulatory Affairs, ERA Consulting und Pharmaberatungs GmbH
|
| 14.30 | Case study: novel areas attracting attention; nanobodies
- Key early stage investment opportunities
- Who is investing where?
- What is the level of interest from big pharma?
|
| |
|
| 15.00 | Case study: novel areas attracting attention; stem cells
- A review of the latest stem call techniques and therapies
- Research being carried out in universities and centres of excellence
- Who is already partnering in this area?
- How can pharmaceutical companies work with niche biotechs and universities to develop this research?
|
| | Chris Mason, Regenerative Medicine Bioproessing Group, University College London
|
| 15.30 | Afternoon tea
|
| |
|
| 16.15 | Case study: How to drive stem cells to general medicine
- A review of the latest stem call techniques and therapies
- How to apply high-tech logic to stem cell development
- Focusing on promising stem cells markets
- Effective clinical trials
- How to select partners for company development
|
| | Zami Aberman, President and Chief Executive Officer, Pluristem Life Systems Inc
|
| 16.45 | Outlook for 2007 and beyond
- What is the outlook for partnering and acquisitions in 2007?
- What are the hot areas for partnering?
- Will the market favor partnerships or acquisitions?
|
| | Hermann Katinger, Chief Executive Officer, POLYMUN Scientific Immunobiologische Forschung GmbH
|
| 17.15 | Chairman’s closing remarks and close of congress
|
| |
|
